查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609604

抗体契约製造市场规模、份额、趋势分析报告：按产品、原产地、最终用途、地区、细分市场预测，2025-2030

Antibodies Contract Manufacturing Market Size, Share & Trends Analysis Report, By Product (Monoclonal Antibodies, Polyclonal Antibodies, Others), By Source, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

抗体契约製造市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球抗体契约製造市场规模预计将达到317.6亿美元，2025年至2030年复合年增长率为10.1%。

治疗性抗体生产的需求不断增加是预测期内推动市场成长的主要因素。抗体是精确针对异常细胞的关键生物製药。于是，许多生物製药公司开始专注于开发先进的抗体来治疗癌症、关节炎、风湿性心臟疾病等慢性疾病。由于单株抗体疗法用于治疗 COVID-19 患者，COVID-19 的影响正在推动市场成长。

主要企业抗体製造研发预算的快速增加也推动了市场成长。在持续对抗 COVID-19 的斗争中，单株抗体 (mAb) 疗法已被证明是一种有效的治疗方法。这种治疗的目标是防止住院、减少病毒量并最大程度地减轻症状的严重程度。

在冠状病毒大流行期间，生物製药公司的供应链仍然强劲，并且在全球范围内基本上没有受到影响。同样，抗体契约製造製造商也发现，用于生产与 COVID-19 疫苗和疗法相关的抗体的需求不断增加。由此可见，未来抗体契约製造市场蕴藏着许多商机。例如，2021 年 12 月，三星生物製品公司与阿斯特捷利康签署了一项协议，生产 Evusheld，这是一种二元抗体组合，正在开发用于潜在治疗 COVID-19。

CMO 的成长高度依赖生物製药产业提供的机会。生命科学领域创业投资的扩张和整合是预计推动市场发展的两个关键机会。例如，2022 年，FUJIFILM Diosynth Biotechnologies 宣布在北卡罗来纳州扩张。透过此次扩张，该公司计划在 2024 年增加其技术职位，包括研究人员和科学家，并创建强大的商业流程。

抗体契约製造市场报告亮点

  • 由于哺乳动物表现系统在生技药品开发中的高渗透率，基于单株抗体的抗体契约製造在 2024 年占据了最大的市场占有率，约为 76.42%。
  • 根据该市场提供的资料，哺乳动物细分市场在 2024 年将占据最大份额，达到 57.52%，因为它被认为更可靠、稳健且相对成熟的技术。
  • 随着印度、韩国和中国等新兴经济体拥抱发展以保持竞争力，预计亚太地区将成为预测期内成长最快的区域市场。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 抗体契约製造市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 产业挑战
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 分析

第四章 抗体契约製造市场：产品预估及趋势分析

  • 细分仪表板
  • 产品变异分析
  • 按产品划分，2018-2030
  • 单株抗体
  • 多株抗体
  • 其他的

第五章 起源商业分析

  • 细分仪表板
  • 起源变异分析
  • 按来源地划分，2018-2030
  • 哺乳动物起源
  • 微生物

第 6 章最终用途业务分析

  • 细分仪表板
  • 最终用途变化分析
  • 按最终用途划分，2018-2030
  • 生物製药公司
  • 研究实验室
  • 其他的

第七章 抗体契约製造市场：区域估算与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 参与企业
  • 策略规划
  • 2024 年企业市场分析（企业热图分析）
  • 公司简介
    • Lonza
    • Samsung Biologics
    • WuXi Biologics
    • Charles River Laboratories
    • FUJIFILM Holdings Corporation
    • Boehringer Ingelheim GmbH
    • AGC Biologics
    • Cytovance Biologics, Inc.
    • EMERGENT
    • Thermo Fisher Scientific, Inc.
    • Catalent, Inc
    • Laboratory Corporation of America Holdings
Product Code: GVR-4-68039-920-3

Antibodies Contract Manufacturing Market Growth & Trends:

The global antibody contract manufacturing market size is expected to reach USD 31.76 billion by 2030, registering a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rise in demand for the production of therapeutic antibodies is the main factor that will drive the growth of the market during the forecast period. Antibodies are the leading biopharmaceutical products that precisely target abnormal cells. Thus, many biopharmaceutical companies have begun to focus on the development of advanced antibodies for the treatment of chronic diseases such as cancer, arthritis, and rheumatic heart disease. The impact of COVID-19 has boosted the market growth, with the application of monoclonal antibodies therapy used as a treatment for COVID-19 patients.

A surge in the R&D budget for the production of antibodies by key players is also driving the growth of the market. For the ongoing fight against COVID-19, Monoclonal antibody (mAb) therapy is proven to be an effective treatment. The aim of this treatment is to prevent hospitalizations, decrease viral loads, and minimize symptom severity.

During the coronavirus outburst, the supply chain of biopharmaceutical companies remained robust and was largely unaffected worldwide. Similarly, antibody contract manufacturers are observing a rise in demand for the production of antibodies that will be used for treatments related to the COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the antibody contract manufacturing market. For instance, in December 2021, an agreement was formed between Samsung Biologics and AstraZeneca to manufacture Evusheld, which is an amalgamation of binary antibodies in development for the potential treatment of COVID-19.

The growth of CMOs is greatly dependent on favorable opportunities offered by the biopharmaceutical industry. Expansion and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2022, FUJIFILM Diosynth Biotechnologies announced an expansion in North Carolina; with this expansion, the company will increase skilled positions including researchers and scientists by 2024 to generate strong commercial processes

Antibodies Contract Manufacturing Market Report Highlights:

  • Monoclonal antibodies-based antibody contract manufacturing captured the largest market share about 76.42% in 2024, owing to the high penetration of mammalian expression systems for biologics development
  • Based on the source offered in this market, the mammalian segment contributed the largest share of 57.52% in 2024, as they are considered a more reliable, robust, and relatively mature technology
  • Asia Pacific is expected to emerge as the fastest-growing regional market during forecast period, owing to developing economies such as India, South Korea, and China incorporating developments to sustain the competition

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Antibody Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
    • 3.2.2. Market Restraints Analysis
    • 3.2.3. Industry Challenges
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Analysis

Chapter 4. Antibody Contract Manufacturing Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Product Movement Analysis
  • 4.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by Product, 2018 - 2030 (USD Million)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Monoclonal Antibodies Market Estimates & Forecasts, by Source, 2018 - 2030 (USD Million)
  • 4.5. Polyclonal Antibodies
    • 4.5.1. Polyclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Source Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Source Movement Analysis
  • 5.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by Source, 2018 - 2030 (USD Million)
  • 5.4. Mammalian Source
    • 5.4.1. Mammalian Source Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Microbial
    • 5.5.1. Microbial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. End Use Movement Analysis
  • 6.3. Antibody Contract Manufacturing Market Estimates & Forecasts, by End Use, 2018 - 2030 (USD Million)
  • 6.4. Biopharmaceutical Companies
    • 6.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Research Laboratories
    • 6.5.1. Research Laboratories Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Antibody Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional market share analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Landscape
      • 7.3.2.4. U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Landscape
      • 7.3.3.4. Canada Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Landscape
      • 7.3.4.4. Mexico Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Landscape
      • 7.4.2.4. UK Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Landscape
      • 7.4.3.4. Germany Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Landscape
      • 7.4.4.4. France Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Landscape
      • 7.4.5.4. Italy Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Landscape
      • 7.4.6.4. Spain Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Landscape
      • 7.4.7.4. Denmark Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Landscape
      • 7.4.8.4. Sweden Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Landscape
      • 7.4.9.4. Norway Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Landscape
      • 7.5.2.4. China Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Japan
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Landscape
      • 7.5.3.4. Japan Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Landscape
      • 7.5.4.4. India Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Landscape
      • 7.5.5.4. South Korea Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Australia
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Landscape
      • 7.5.6.4. Australia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Landscape
      • 7.5.7.4. Thailand Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Landscape
      • 7.6.2.4. Brazil Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Landscape
      • 7.6.3.4. Argentina Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Middle East and Africa
    • 7.7.1. Middle East and Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Landscape
      • 7.7.2.4. Saudi Arabia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Landscape
      • 7.7.3.4. UAE Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.4. South Africa
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Landscape
      • 7.7.4.4. South Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Landscape
      • 7.7.5.4. Kuwait Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
  • 8.4. Company Profiles
    • 8.4.1. Lonza
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Service Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Samsung Biologics
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Service Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. WuXi Biologics
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Service Benchmarking
    • 8.4.4. Charles River Laboratories
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Service Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. FUJIFILM Holdings Corporation
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Service Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Boehringer Ingelheim GmbH
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Service Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. AGC Biologics
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Service Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Cytovance Biologics, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Service Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. EMERGENT
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Service Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Thermo Fisher Scientific, Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Service Benchmarking
      • 8.4.10.4. Strategic Initiatives
      • 8.4.10.5. Strategic Initiatives
    • 8.4.11. Catalent, Inc
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Service Benchmarking
      • 8.4.11.4. Strategic Initiatives
    • 8.4.12. Laboratory Corporation of America Holdings
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Service Benchmarking
      • 8.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 4 Global Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 5 Global Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 6 Global Antibody Contract Manufacturing, by Region, 2018 - 2030 (USD Million)
  • Table 7 U.S. Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 8 U.S. Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 9 U.S. Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 10 U.S. Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 11 U.S. Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 12 U.S. Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 13 U.S. Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 14 U.S. Canada Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 15 Canada Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 16 Canada Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Mexico Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 18 Mexico Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 19 Mexico Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Europe Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 22 Europe Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 23 Europe Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Germany Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 25 Germany Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 26 Germany Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 27 UK Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 28 UK Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 29 UK Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 30 France Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 31 France Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 32 France Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Italy Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 34 Italy Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 35 Italy Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 36 Spain Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 37 Spain Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 38 Spain Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 39 Denmark Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 40 Denmark Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 41 Denmark Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Sweden Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 43 Sweden Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 44 Sweden Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Norway Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 46 Norway Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 47 Norway Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 52 China Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 53 China Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 54 China Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 55 Japan Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 56 Japan Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 57 Japan Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 58 India Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 59 India Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 60 India Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 61 South Korea Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 62 South Korea Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 63 South Korea Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 64 Australia Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 65 Australia Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 66 Australia Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Thailand Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 68 Thailand Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 69 Thailand Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 70 Latin America Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 72 Latin America Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 73 Latin America Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 74 Latin America Antibody Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 75 Brazil Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 76 Brazil Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 77 Brazil Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 79 Argentina Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 80 Argentina Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Antibody Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 86 South Africa Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 87 South Africa Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 91 UAE Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 92 UAE Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 93 UAE Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)
  • Table 94 UAE Antibody Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Antibody Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Antibody Contract Manufacturing, by Product, 2018 - 2030 (USD Million)
  • Table 97 Kuwait Antibody Contract Manufacturing, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Antibody Contract Manufacturing, Market Segmentation
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Market Dynamics
  • Fig. 8 Market Driver Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 PESTEL Analysis, By SWOT Analysis
  • Fig. 12 Regional Marketplace: Key Takeaways
  • Fig. 13 Global Antibody Contract Manufacturing, for Monoclonal Antibodies, 2018 - 2030 (USD Million)
  • Fig. 14 Global Antibody Contract Manufacturing, for Polyclonal Antibodies, 2018 - 2030 (USD Million)
  • Fig. 15 Global Antibody Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Fig. 16 Global Antibody Contract Manufacturing, for Mammalian, 2018 - 2030 (USD Million)
  • Fig. 17 Global Antibody Contract Manufacturing, for Microbial, 2018 - 2030 (USD Million)
  • Fig. 18 Global Antibody Contract Manufacturing, for Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Antibody Contract Manufacturing, for Research Laboratories, 2018 - 2030 (USD Million)
  • Fig. 20 Global Antibody Contract Manufacturing, for others, 2018 - 2030 (USD Million)
  • Fig. 21 Regional Outlook, 2024 & 2030
  • Fig. 22 U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Italy Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Denmark Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 India Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Japan Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 South Korea Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Colombia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Middle East & Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 South Africa Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UAE Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Kuwait Antibody Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)